Literature DB >> 21409414

Advanced glycation end-products induce basement membrane hypertrophy in endoneurial microvessels and disrupt the blood-nerve barrier by stimulating the release of TGF-β and vascular endothelial growth factor (VEGF) by pericytes.

F Shimizu1, Y Sano, H Haruki, T Kanda.   

Abstract

AIMS/HYPOTHESIS: The breakdown of the blood-nerve barrier (BNB) is considered to be a key step in diabetic neuropathy. Although basement membrane hypertrophy and breakdown of the BNB are characteristic features of diabetic neuropathy, the underlying pathogenesis remains unclear. The purpose of the present study was to identify the possible mechanisms responsible for inducing the hypertrophy of basement membrane and the disruption of the BNB after exposure to AGEs.
METHODS: The newly established human peripheral nerve microvascular endothelial cell (PnMEC) and pericyte cell lines were used to elucidate which cell types constituting the BNB regulate the basement membrane and to investigate the effect of AGEs on the basement membrane of the BNB using western blot analysis.
RESULTS: Fibronectin, collagen type IV and tissue inhibitor of metalloproteinase (TIMP-1) protein were produced mainly by peripheral nerve pericytes, indicating that the basement membrane of the BNB is regulated mainly by these cells. AGEs reduced the production of claudin-5 in PnMECs by increasing autocrine signalling through vascular endothelial growth factor (VEGF) secreted by the PnMECs themselves. Furthermore, AGEs increased the amount of fibronectin, collagen type IV and TIMP-1 in pericytes through a similar upregulation of autocrine VEGF and transforming growth factor (TGF)-β released by pericytes. CONCLUSIONS/
INTERPRETATION: These results indicate that pericytes may be the main regulators of the basement membrane at the BNB. AGEs induce basement membrane hypertrophy and disrupt the BNB by increasing autocrine VEGF and TGF-β signalling by pericytes under diabetic conditions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21409414     DOI: 10.1007/s00125-011-2107-7

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  43 in total

Review 1.  Advanced glycation end products: sparking the development of diabetic vascular injury.

Authors:  Alison Goldin; Joshua A Beckman; Ann Marie Schmidt; Mark A Creager
Journal:  Circulation       Date:  2006-08-08       Impact factor: 29.690

Review 2.  Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy.

Authors:  N E Cameron; S E Eaton; M A Cotter; S Tesfaye
Journal:  Diabetologia       Date:  2001-11       Impact factor: 10.122

3.  Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice.

Authors:  Sun Hee Sung; Fuad N Ziyadeh; Amy Wang; Petr E Pyagay; Yashpal S Kanwar; Sheldon Chen
Journal:  J Am Soc Nephrol       Date:  2006-09-20       Impact factor: 10.121

4.  Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice.

Authors:  F N Ziyadeh; B B Hoffman; D C Han; M C Iglesias-De La Cruz; S W Hong; M Isono; S Chen; T A McGowan; K Sharma
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

Review 5.  Roles of the receptor for advanced glycation endproducts in diabetes-induced vascular injury.

Authors:  Hideto Yonekura; Yasuhiko Yamamoto; Shigeru Sakurai; Takuo Watanabe; Hiroshi Yamamoto
Journal:  J Pharmacol Sci       Date:  2005-03-05       Impact factor: 3.337

6.  Altered expression of basement membrane-related molecules in rat brain pericyte, endothelial, and astrocyte cell lines after transforming growth factor-beta1 treatment.

Authors:  Noriko Kose; Tomoko Asashima; Mariko Muta; Hisashi Iizasa; Yoshimichi Sai; Tetsuya Terasaki; Emi Nakashima
Journal:  Drug Metab Pharmacokinet       Date:  2007-08       Impact factor: 3.614

Review 7.  RAGE, vascular tone and vascular disease.

Authors:  David G S Farmer; Simon Kennedy
Journal:  Pharmacol Ther       Date:  2009-07-17       Impact factor: 12.310

8.  Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice.

Authors:  K Sharma; Y Jin; J Guo; F N Ziyadeh
Journal:  Diabetes       Date:  1996-04       Impact factor: 9.461

Review 9.  Cellular signaling and potential new treatment targets in diabetic retinopathy.

Authors:  Zia A Khan; Subrata Chakrabarti
Journal:  Exp Diabetes Res       Date:  2007

10.  Inhibition of advanced glycation and absence of galectin-3 prevent blood-retinal barrier dysfunction during short-term diabetes.

Authors:  Paul Canning; Josephine V Glenn; Daniel K Hsu; Fu-Tong Liu; Tom A Gardiner; Alan W Stitt
Journal:  Exp Diabetes Res       Date:  2007
View more
  28 in total

1.  Pericyte-derived glial cell line-derived neurotrophic factor increase the expression of claudin-5 in the blood-brain barrier and the blood-nerve barrier.

Authors:  Fumitaka Shimizu; Yasuteru Sano; Kazuyuki Saito; Masa-aki Abe; Toshihiko Maeda; Hiroyo Haruki; Takashi Kanda
Journal:  Neurochem Res       Date:  2011-10-16       Impact factor: 3.996

2.  Granulocyte/macrophage colony-stimulating factor attenuates endothelial hyperpermeability after thermal injury.

Authors:  Jingling Zhao; Lei Chen; Bin Shu; Jinming Tang; Lijun Zhang; Julin Xie; Xusheng Liu; Yingbin Xu; Shaohai Qi
Journal:  Am J Transl Res       Date:  2015-03-15       Impact factor: 4.060

Review 3.  Diabetic nephropathy and extracellular matrix.

Authors:  S O Kolset; F P Reinholt; T Jenssen
Journal:  J Histochem Cytochem       Date:  2012-10-27       Impact factor: 2.479

Review 4.  Targeting the blood-nerve barrier for the management of immune-mediated peripheral neuropathies.

Authors:  Evan B Stubbs
Journal:  Exp Neurol       Date:  2020-06-17       Impact factor: 5.330

Review 5.  The molecular and biophysical characterization of the human blood-nerve barrier: current concepts.

Authors:  Eroboghene E Ubogu
Journal:  J Vasc Res       Date:  2013-07-06       Impact factor: 1.934

6.  Brain endothelial dysfunction in cerebral adrenoleukodystrophy.

Authors:  Patricia L Musolino; Yi Gong; Juliet M T Snyder; Sandra Jimenez; Josephine Lok; Eng H Lo; Ann B Moser; Eric F Grabowski; Matthew P Frosch; Florian S Eichler
Journal:  Brain       Date:  2015-09-15       Impact factor: 13.501

Review 7.  Sodium-glucose co-transporter 2 inhibitors and diabetic retinopathy: insights into preservation of sight and looking beyond.

Authors:  Sejal Lahoti; Mouhamed Nashawi; Omar Sheikh; David Massop; Mahnoor Mir; Robert Chilton
Journal:  Cardiovasc Endocrinol Metab       Date:  2020-05-18

8.  VEGF-A165 potently induces human blood-nerve barrier endothelial cell proliferation, angiogenesis, and wound healing in vitro.

Authors:  Chetan Lakshmana Reddy; Nejla Yosef; Eroboghene E Ubogu
Journal:  Cell Mol Neurobiol       Date:  2013-05-26       Impact factor: 5.046

Review 9.  Vascular endothelial growth factor: a neurovascular target in neurological diseases.

Authors:  Christian Lange; Erik Storkebaum; Carmen Ruiz de Almodóvar; Mieke Dewerchin; Peter Carmeliet
Journal:  Nat Rev Neurol       Date:  2016-07-01       Impact factor: 42.937

Review 10.  Biologic Basis of Nerve Decompression Surgery for Focal Entrapments in Diabetic Peripheral Neuropathy.

Authors:  John Sessions; D Scott Nickerson
Journal:  J Diabetes Sci Technol       Date:  2014-02-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.